⌘K
t
On December 3, 2024, an employee benefit trust, advised by VG Corporate Trustee Limited, was terminated, resulting in the distribution of Roquefort Therapeutics plc ordinary shares for nil consideration to its beneficiaries. As a result, three directors of Roquefort Therapeutics received shares: Ajan Reginald received 34,432 shares, Dr Darrin Disley received 9,146 shares, and Sir Martin Evans received 2,690 shares. Following this distribution, Ajan Reginald now holds 9.1% of the company's issued capital, Dr Darrin Disley holds 1.5%, and Sir Martin Evans holds 0.0%.
| Date | 4 Dec 2024 |
| Time | 16:00:00 |
| Category | Director/PDMR dealings |
| ID | 8386O |
4 December 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director Share Distribution
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, has been advised by VG Corporate Trustee Limited that an employee benefit trust (unrelated to the Company), has been terminated and the trust assets have been distributed to the beneficiaries. As a result of the trust distribution, three Directors of the Company (Ajan Reginald, Dr Darrin Disley and Sir Marin Evans) have received ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
|
Director |
Number of Ordinary Shares Received for Nil Consideration |
Number of Ordinary Shares Now Held |
% of Company's Issued Capital |
|
Ajan Reginald |
34,432 |
12,346,413 |
9.1% |
|
Dr Darrin Disley |
9,146 |
2,024,196 |
1.5% |
|
Sir Martin Evans |
2,690 |
2,690 |
0.0% |
-ENDS-
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Ajan Reginald (CEO) |
|
|
SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0) 20 3470 0470
|
|
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale |
+44 (0)20 7466 5000
|
|
Peak IR (Investor Relations) Seb Wykeham |
+33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunology and oncology markets prior to partnering with big pharma.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK cell-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Ajan Reginald |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Roquefort Therapeutics plc |
|
|
b) |
LEI |
254900P4SISIWOR9RH34 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 |
|
|
b) |
Nature of the transaction |
Trust distribution of 34,432 ordinary shares |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
0 pence per share |
34,432 |
|
|
d |
Aggregated information - Aggregated volume - Price |
- 34,432 - 0p |
|
|
e) |
Date of the transactions |
3 December 2024 |
|
|
f) |
Place of the transactions |
London Stock Exchange (XLON); Main Market |
|
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Dr Darrin Disley |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Roquefort Therapeutics plc |
|
|
b) |
LEI |
254900P4SISIWOR9RH34 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 |
|
|
b) |
Nature of the transaction |
Trust distribution of 9,146 ordinary shares |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
0 pence per share |
9,146 |
|
|
d |
Aggregated information - Aggregated volume - Price |
- 9,146 - 0p |
|
|
e) |
Date of the transactions |
3 December 2024 |
|
|
f) |
Place of the transactions |
London Stock Exchange (XLON); Main Market |
|
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Sir Martin Evans |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Roquefort Therapeutics plc |
|
|
b) |
LEI |
254900P4SISIWOR9RH34 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 |
|
|
b) |
Nature of the transaction |
Trust distribution of 2,690 ordinary shares |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
0 pence per share |
2,690 |
|
|
d |
Aggregated information - Aggregated volume - Price |
- 2,690 - 0p |
|
|
e) |
Date of the transactions |
3 December 2024 |
|
|
f) |
Place of the transactions |
London Stock Exchange (XLON); Main Market |
|